3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
307
Lung Neoplasms
111
Adenocarcinoma of Lung
23
Non-Squamous Non-Small Cell Lung Cancer
21
Neoplasms
21
Adenocarcinoma, Bronchiolo-Alveolar
15
Brain Neoplasms
14
Neoplasm Metastasis
10
Squamous Cell Carcinoma of Head and Neck
5
Respiratory Tract Diseases
5
Carcinoma
5
Breast Neoplasms
5
Adenocarcinoma
5
Thoracic Neoplasms
4
Recurrence
4
Pancreatic Neoplasms
4
NSCLC
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Salivary Gland Neoplasms
3
Respiratory Tract Neoplasms
3
Rectal Neoplasms
3
Lung Diseases
3
Esthesioneuroblastoma, Olfactory
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Thymoma
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Pleural Effusion, Malignant
2
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Erlotinib Hydrochloride
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA